Expert-pathologist confirmation recommended

Expert gastrointestinal pathology confirmation is recommended for any diagnosis of low-grade dysplasia (LGD) prior to authorization of endoscopic eradication therapy (EET). Document that LGD was confirmed by an expert pathologist and include prior surveillance history (number and dates of endoscopies/biopsies). Patients without expert-pathologist confirmation of LGD may not meet selection criteria used in major trials and may be ineligible for coverage of RFA for LGD.

• Require documentation of expert-pathologist review for LGD cases
• If expert confirmation absent, note potential denial or need for additional confirmatory biopsies

Prior authorization for confirmatory endoscopy

If Cytosponge-TFF3 testing is used and returns a positive result, prior authorization should document the positive result and the referral for confirmatory diagnostic endoscopy. Note that offering Cytosponge in screening will increase the number of confirmatory endoscopies; provide justification when seeking coverage.

• Attach Cytosponge test result (TFF3 positive) and referral note for endoscopy
• Document clinical rationale for proceeding to endoscopy after Cytosponge

Prior authorization recommended for adjunctive advanced imaging

Use of adjunctive advanced imaging (e.g., volumetric laser endomicroscopy [VLE], OCT) should be accompanied by prior-authorization documentation that includes prior diagnostic testing, rationale for the adjunctive imaging, and how results will change management. Advanced imaging cannot generally replace the Seattle protocol unless the operator has documented meeting PIVI performance thresholds.

• Provide prior diagnostic biopsy results and indication for adjunctive imaging (e.g., unexplained suspicion on white-light endoscopy)
• If claiming replacement of Seattle protocol, include documentation that operator met PIVI thresholds (sensitivity ≥90%, NPV ≥98%, specificity ≥80%)

WATS/WATS3D may require prior authorization

Wide-area transepithelial sampling (WATS/WATS3D) may increase dysplasia detection but the clinical significance of WATS-only dysplasia is uncertain. Prior authorization may be appropriate; when submitted, include concurrent forceps biopsy results and plan for confirmatory histology.

• If coverage requested based on WATS-only positive findings, include plan for confirmatory forceps biopsy and subsequent management
• Document whether WATS was adjunctive to standard four-quadrant biopsies

Prior authorization not specified

Some sections of the evidence base and administrative content do not specify prior-authorization or billing requirements. In these cases, follow standard payer rules; include complete clinical documentation when requesting authorization.

• No explicit prior authorization rule in certain study descriptions — rely on payer-specific prior auth guidelines
• Provide full clinical records when in doubt

Denial triggers — experimental/investigational interventions

Interventions and technologies described in this policy as experimental or investigational (and therefore potential denial triggers) include argon plasma coagulation (APC), cryotherapy/cryoablation (when used outside accepted salvage indications), optical coherence tomography (OCT)/VLE without validated protocols, Cytosponge for routine surveillance, Barrett’s esophagus FISH assays, DNA-methylation prognostic assays, and other novel biomarkers and imaging modalities.

• List of examples: APC, cryotherapy/cryoablation (except where listed as medically necessary/salvage per policy), OCT/VLE without validated protocol, Cytosponge for screening outside specified pathways, FISH assays (MolDX)
• Experimental coding/status noted in CPT/HCPCS sections may be not covered

Uncertain long-term efficacy

Long-term efficacy evidence is limited or uncertain for many ablative techniques other than RFA and PDT. When prior authorization is sought for interventions lacking long-term data, include supportive evidence and rationale; absence of such evidence may result in denial.

• RFA and PDT have longer-term data; many newer or less-studied modalities lack proven cancer-risk reduction
• Document long-term follow-up data when available to support requests

Patients without expert-pathologist confirmation

Patients diagnosed with LGD who lack expert-pathologist confirmation should have additional confirmatory biopsies or expert review before consideration for ablation. Trial selection criteria required expert confirmation; absence of this may preclude coverage for RFA in LGD.

• Document steps taken to obtain expert pathology review or repeat endoscopy/biopsy
• Note that many patients initially reported as LGD are downgraded on expert review

Replacement of Seattle protocol — performance expectation

Advanced imaging techniques should not replace the Seattle 4-quadrant biopsy protocol unless the operator demonstrates validated performance that meets PIVI thresholds. Documentation of operator training, validation, and per-operator performance (sensitivity/NPV/specificity) is expected when using imaging to supplant random biopsies.

• Provide operator performance metrics and validation studies if claiming replacement of Seattle protocol
• If PIVI thresholds are not met, include standard 4-quadrant biopsies in the plan

Insufficient comparative evidence

Novel ablative tools and imaging technologies without robust comparative evidence versus established therapies are considered investigational. Prior-authorization requests for such technologies should include high-quality comparative data; lacking that, requests may be denied.

• Provide prospective comparative studies if available
• Otherwise, expect investigational determination and potential denial

Confirmatory endoscopy after positive Cytosponge

BEST3 and other Cytosponge trials demonstrated increased detection of Barrett's esophagus but also led to increased endoscopies. Prior-authorization submissions after Cytosponge positives should include the test result, referral documentation, and planned diagnostic/therapeutic steps.

• Attach Cytosponge-TFF3 positive report and clinical referral note
• Document anticipated downstream procedures (endoscopy, biopsy, therapy)

Evidence limitations may trigger denial

Limitations in the evidence base (lack of standardized protocols, short follow-up, operator experience concentrated in referral centers) may prompt denial or requests for additional justification. When requesting authorization for modalities with limited supportive data, include protocol details and follow-up plans.

• Provide standardized imaging/biopsy protocol when available
• Include planned follow-up interval and surveillance strategy

Uncertain clinical significance and limits of WATS-only findings

Clinical significance of WATS-only detected dysplasia is uncertain; prior-authorization or coverage may require confirmatory forceps biopsies and documentation of subsequent histology to guide management decisions.

• If WATS-only dysplasia reported, submit plans for confirmatory FB biopsies and targeted management
• Document any available re-confirmation histology results

No explicit authorization or billing requirements in some source text

Some study reports and administrative sections describe research findings without explicit billing or authorization rules. For operational questions, follow payer-specific prior authorization and coding policies; include full clinical documentation when requesting coverage.

• No step-therapy or billing rules presented in parts of the source — use standard payer procedures
• When in doubt, include complete clinical records and rationale

Not applicable content in this section

This section contains background, evidence summaries, and administrative notes that are informational and not actionable coverage rules. Use the provider-action callouts above for authorization and documentation requirements.

• Policy history and additional information are administrative — see header for effective and next review dates

Documentation for RFA in LGD

For radiofrequency ablation (RFA) in LGD, document histologic confirmation of LGD on two or more endoscopies at least 3 months apart. Include grade of dysplasia, dates/results of prior surveillance endoscopies, and the indication for ablation in authorization requests.

• Provide ≥2 endoscopy/biopsy reports showing LGD separated by ≥3 months
• Include prior surveillance history and rationale for RFA

Required clinical documentation

Required clinical documentation for authorization requests should include dysplasia grade, prior treatments, prior surveillance results, indication for ablation, acid-suppression therapy details, and expert-pathology reports where applicable.

• List required items: dysplasia grade, dates/results of prior endoscopies/biopsies, prior endoscopic/surgical treatments, current PPI regimen and response, expert pathology consultation reports

Documentation of histologic confirmation

Histologic confirmation of intestinal metaplasia and accurate dysplasia classification (LGD versus HGD) is necessary to guide management and prior-authorization decisions. Include biopsy pathology reports and any expert second opinions in submissions.

• Attach pathology reports confirming intestinal metaplasia and dysplasia grade
• Include expert second-opinion pathology when obtained

Operator validation and performance documentation

When advanced imaging or replacement of standard protocols is claimed, document operator validation, training, and performance meeting PIVI thresholds or an accepted validated-equivalent. Include center volume or operator experience if relevant.

• Provide operator-level performance metrics (sensitivity, NPV, specificity) or evidence of having met PIVI thresholds
• Document endoscopist volume and advanced imaging experience

Required clinical documentation for cryotherapy cases

For cryotherapy cases, authorization submissions should include prior treatment history (number and type of prior ablation sessions, including RFA), histopathology, and the number of prior sessions. Cryotherapy is primarily considered salvage therapy after RFA failure; primary use may require stronger justification.

• Document number and dates of prior RFA or other ablation sessions
• Attach histopathology confirming persistent dysplasia or IM
• Specify whether cryotherapy is primary or salvage therapy

Required documentation for FISH assay

When FISH assays (e.g., MolDX) are submitted for consideration, include indication, specimen type (brush cytology or biopsy), and any concurrent biopsy/histology results. FISH is considered investigational by this policy context and may be denied without evidence of clinical utility in the specific case.

• Provide specimen type and concurrent histology/biopsy results
• Include rationale for FISH use and how results will affect management

Document Cytosponge result and referral for endoscopy

If Cytosponge-TFF3 is used, document the Cytosponge result and the referral for endoscopy. Because Cytosponge screening increases endoscopy rates, include clinical justification for proceeding to endoscopy when seeking coverage for downstream procedures.

• Attach Cytosponge-TFF3 result and referral note
• Provide justification for confirmatory endoscopy and planned next steps

Required supporting documentation

Supporting documentation for registry or post-market device use should include the protocol used, imaging interpretation criteria, tissue acquisition strategy, and follow-up plans. Many registry reports lacked standardized protocols; include these details when seeking authorization.

• Provide imaging and biopsy protocol, image interpretation criteria, and planned surveillance intervals
• If participating in a registry, include registry protocol and governance information

Assay documentation

For molecular and multi-gene assays (e.g., DNA methylation panels, Esopredict, multi-gene methylation tests), describe development, validation, intended use population, specimen types, and how results will alter surveillance or treatment. These assays are generally considered investigational unless validated with demonstrated clinical utility.

• Include validation studies, intended clinical use, and evidence linking assay results to management changes
• If assay results will change surveillance intervals or trigger ablation, document the decision algorithm

Policy history and administrative notes

Policy history, review dates, and administrative notes are provided in the Additional Information and Policy History sections. These are administrative and do not substitute for clinical documentation required for prior authorization.

• Effective date: 2006-10-13; Next Review: 08/08/2024
• Use clinical callouts above for authorization actions

Therapy escalation and surgical/treatment sequencing considerations

Therapy escalation should follow standard sequencing: optimize acid suppression and anti-reflux measures, perform EMR for visible/nodular lesions prior to ablative monotherapy, consider combined EMR + ablation for nodular HGD, reserve esophagectomy for selected candidates or multifocal/submucosal invasion, and consider endoscopic therapy (RFA preferred) over esophagectomy for most HGD when feasible.

• Optimize PPI therapy prior to ablation and document regimen and response
• EMR for visible lesions should be performed before ablative monotherapy
• Esophagectomy remains gold standard for selected patients (e.g., submucosal invasion)

Prefer RFA before cryotherapy; RFA preferred first-line before cryotherapy

Evidence and guideline summaries favor radiofrequency ablation (RFA) as the preferred first-line endoscopic ablative therapy for dysplastic BE (HGD and selected LGD). Cryotherapy is generally considered a salvage option after RFA failure and primary cryotherapy requests should include robust justification.

• RFA preferred first-line for dysplastic BE (HGD and selected LGD)
• Cryotherapy primarily salvage; primary cryotherapy requires stronger evidence and may be investigational

No step therapy rules presented / Not specified

No specific step-therapy rules (e.g., mandatory trials of alternate modalities before ablation) are presented in the source text. Coverage decisions should follow payer criteria and the clinical documentation requirements outlined above.

• No explicit step-therapy algorithms provided in this section
• Follow payer-specific prior authorization and clinical-necessity criteria

Suggested stepwise testing approach

A suggested stepwise testing approach described in the evidence includes triage with non-endoscopic tests (e.g., Cytosponge) followed by confirmatory endoscopy for positives, and use of adjunctive imaging or molecular assays as add-ons with documented impact on management.

• Cytosponge triage → confirmatory endoscopy if positive
• Adjunctive imaging or assays require evidence they will change management and should be documented

Because the clinical significance of WATS-only findings is uncertain

Because the clinical significance of WATS-detected dysplasia (WATS-only) is unclear and reconfirmation rates with forceps biopsy are limited, authorization requests based solely on WATS findings should include a reconfirmation plan and may be questioned or denied without confirmatory histology.

• Plan for follow-up forceps biopsies to confirm WATS-only dysplasia
• Document management intentions pending reconfirmation

No explicit authorization or billing requirements specified in the source

No universal authorization/billing instructions are specified in the source; providers should follow payer-specific prior authorization pathways. Include all required clinical documentation (see documentation callouts) when submitting requests.

• Follow Aetna prior authorization processes and attach complete clinical documentation
• Claims coding should reference covered CPT/HCPCS only when selection criteria are met